| Home Market Dynamics Sector Analysis Company Insights AI Investing Strategies Contact Us Login |
| Eli Lilly has demonstrated a strong commitment to innovation in pharmaceutical offerings, particularly through the successful development of GLP-1 medications and the momentum of its popular weight-loss drugs, Mounjaro and Zepbound. The company is also actively expanding its manufacturing capabilities, which signals confidence in future product demand and revenue growth. Anticipation for upcoming treatments further reinforces a positive market outlook, while the pipeline in diabetes and obesity drugs presents significant potential for sustained progress. However, maintaining a competitive edge in the rapidly evolving pharmaceutical landscape remains a critical challenge. |
| The price action of Eli Lilly (LLY) is impacted by broad market risk appetite, sector price trend, company-specific performance and market structure. The market sentiment at 0.6 is bullish. Trend sentiment measures the current trend of the stock price, and market sentiment reflects what market participants collectively think where the price will move next.There is no clear direction for LLY since trend sentiment and market sentiment are at the opposite directions. The positive sentiment force for sector is at 0.8, and the negative at -0.2 on 2025-11-05. The forces of and Valuation Sentiment (-1) will drive down the price. The forces of Stock Price Trend (0), Sector Price Trend (0), Price Level Sentiment (0), Option Sentiment (0), Market Risk Appetite (0), and Sentiment towards Fundamentals (4.7) will drive up the price. The sentiment for Sector Price Trend is calculated based on the price trend of related sector ETF. The sentiment for Option Speculation is calculated from put/call ratio. The Risk Appetite is calculated from Bitcoin price trend. Price Level sentiment is positive when oversold, and negative when overbought. Valuation Sentiment, and Sentimentals towards Fundamentals are extracted from headlines and market commentary. All sentiment scores are normalized on a -10 - +10 scale. The price level reaches 100 at Bollinger upper band, and zero at lower band. |
| LLY | |||||||||||||
| Date | Attention | Price | Price Level | Change | SMA10 Trend | Trend Sentiment | Hourly Trend | Hourly StdDev | Market Sentiment | Action | P | Fund. | News Sentiment |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-11-05 | 0%(0.1%) | 0 | 0% | 0.6 | 4.7 | -1 | |||||||
| 2025-11-04 | 0%(0.1%) | 0 | 0% | 0.6 | 4.7 | 5.3 | |||||||
| 2025-11-03 | 0%(0.1%) | 0 | 0% | 0.6 | 4.8 | -1 | |||||||
| 2025-11-02 | 0%(0.1%) | 0 | 0% | 0.6 | 4.7 | -1 | |||||||
| 2025-11-01 | 0%(0.1%) | 0 | 0% | 0.6 | 4.6 | -1 | |||||||
| 2025-10-31 | 0%(0.1%) | 0 | 0% | 0.6 | 4.4 | 6.5 | |||||||
| 2025-10-30 | 1%(0.1%) | 0 | 0% | 0.6 | 4.4 | 6.8 | |||||||
| 2025-10-29 | 0%(0%) | 0 | 0% | 0.5 | 3.8 | 7 | |||||||
| 2025-10-28 | 0%(0%) | 0 | 0% | 0.4 | 3.5 | 5.5 | |||||||
| 2025-10-27 | 0%(0%) | 0 | 0% | 0.4 | 3.2 | -1 | |||||||
| Wait action is recommended in three scenarios with either high uncertainty or high risk: 1. The trend sentiment and market sentiment are at the opposite directions. 2. Both trend sentiment and market sentiment are positive, but the price level is elevated. 3. Both trend sentiment and market sentiment are negative, but the price level is depressed. In an uptrend, as an investor, you may want to wait for the pullback to open long position. In a downtrend, the price will likely rebound after huge decline. As an investor, you may want to wait for the rebound to exit long position. | |||||||||||||
| Market sentiment will accelerate the current trend when both trend sentiment and market sentiment are at the same direction. Market sentiment will generate volatility when it's at the opposite direction of the trend sentiment. News sentiment measures the daily emotion of the market. News sentiment may impact the daily price change while market sentiment is a more stable and consistent moving force. | |||||||||||||
| 2025-11-05 17:02:25 There's a focus on the development of new treatments, especially Tirzepatide, which addresses both diabetes and obesity, showcasing innovation in drug offerings. |
| 2025-11-05 17:02:25 The involvement of government officials and potential regulation changes regarding drug pricing are significant themes appearing in the articles. |
| 2025-11-05 17:02:25 Collaborations between Eli Lilly and other companies, like Ailux, are aimed at advancing drug development and innovation in the healthcare sector. |
| 2025-11-05 17:02:25 Eli Lilly's stock performance is noted as positive, showing an upward trend and overall strong momentum in the market. |
| 2025-11-05 17:02:25 The articles discuss ongoing negotiations and agreements aimed at reducing the cost of obesity drugs, highlighting potential access for Medicare and Medicaid beneficiaries. |